木瓜直播

No additional risk in older adults newly prescribed the drug, comparative analysis shows

Benefits from 3-month online intervention lasted 2 years, but trial lacked control group

Maybe not a form of long COVID, but a concern just the same

But maybe all is not lost

More phase II data build case for izokibep

Study suggests 10% of cases may have easily treatable cause

Publication comes after another study's failure to demonstrate benefit

Question remains: why?

With marked symptom reduction in just 3 weeks, weight loss not a factor

Almost one-third of patients in Italian study had musculoskeletal sequelae

TV host takes leave of absence

Typical 7-year delay after symptom onset leaves patients at risk for irreversible damage

But overall prescriptions for pain meds have tapered off over the years

Pandemic highlights the need for tailored approaches